The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Estrogen receptor (ER), Ki-67, p27Kip1, and histologic grade as predictors of pathologic complete response (pCR) in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy (NAC) using fluorouracil, epirubicin, and cyclophosphamide (FEC), taxanes, and trastuzumab.
Sasagu Kurozumi
No relevant relationships to disclose
Kenichi Inoue
No relevant relationships to disclose
Hiroyuki Takei
No relevant relationships to disclose
Hiroshi Matsumoto
No relevant relationships to disclose
Takashi Yoshida
No relevant relationships to disclose
Yuji Hayashi
No relevant relationships to disclose
Jun Ninomiya
No relevant relationships to disclose
Kazuyuki Kubo
No relevant relationships to disclose
Shigenori E Nagai
No relevant relationships to disclose
Hanako Oba
No relevant relationships to disclose
Masafumi Kurosumi
No relevant relationships to disclose
Toshio Tabei
No relevant relationships to disclose
Jun Horiguchi
No relevant relationships to disclose
Izumi Takeyoshi
No relevant relationships to disclose